Investor Kit

Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
05/10/18
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
02/02/113Initial filing by director officer or owner of more than ten percent.3,4,5 Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/02/113Initial filing by director officer or owner of more than ten percent.3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/02/113Initial filing by director officer or owner of more than ten percent.3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/02/113Initial filing by director officer or owner of more than ten percent.3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/02/113Initial filing by director officer or owner of more than ten percent.3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
05/03/18Pacira Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results
-- EXPAREL® net product sales of $74.0 million up 9% over prior year first quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 03, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the first quarter ended March 31, 2018. “2018 is off to a terrific start with EXPAREL daily sales volumes accelerating from 6 percent in January to 15 percent in March, as well as a recently expanded label that now inclu... 
Printer Friendly Version
05/01/18Pacira Pharmaceuticals to Present at Two Healthcare Conferences in May
PARSIPPANY, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences: Deutsche Bank 43rd Annual Health Care Conference in Boston, on Wednesday, May 9 at 2:10 PM ET Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, on Tuesday, May 15, at 1:40 PM PT (4:40PM ET) A live audio webcast of the Pacira presentations can be ac... 
Printer Friendly Version
04/26/18Pacira Pharmaceuticals Announces Timing for First Quarter 2018 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 3, 2018. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. The call can be accessed by dialing 1-... 
Printer Friendly Version
04/06/18Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® as a Nerve Block to Produce Regional Analgesia
EXPAREL is now an opioid-free option for use as an interscalene brachial plexus block for upper extremity surgeries Conference call on Monday, April 9, 2018 at 8:30 a.m. EST PARSIPPANY, N.J., April 06, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to broaden the use of EXPAREL® (bupivacaine liposome injectable suspension) to include administratio... 
Printer Friendly Version
03/06/18Pacira Pharmaceuticals to Present at the 2018 Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to participate in an analyst-led fireside chat at the 2018 Barclays Global Healthcare Conference at 11:15 AM ET on Tuesday, March 13, 2018 in Miami. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on... 
Printer Friendly Version
02/28/18Pacira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
-- EXPAREL® net product sales expected to be in the range of $300 to $310 million in 2018 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported financial results for the fourth quarter and full year of 2017 and its outlook for 2018. “2017 was a year of solid progress and set the stage for an important year ahead,” said Dave Stack, chairman and chief executive officer of Pacira. “EXPAREL ... 
Printer Friendly Version
02/27/18University of Tennessee Medical Center at Knoxville, Pacira Pharmaceuticals, and CQ-Insights Announce Collaboration to Minimize Opioid Use After Hernia Surgery
Continuous quality improvement project aims to optimize patient outcomes after hernia repair PARSIPPANY, N.J. and KNOXVILLE, Tenn., Feb. 27, 2018 (GLOBE NEWSWIRE) -- To improve patient outcomes and combat a segment of the national opioid epidemic, The University of Tennessee Medical Center and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a continuous quality improvement (CQI) project designed to develop low- or no-opioid postsurgical pain management pathways for patients under... 
Printer Friendly Version
02/22/18Pacira Pharmaceuticals Announces Timing for 2017 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2017 financial results before the open of the U.S. markets on Wednesday February 28, 2018. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. ... 
Printer Friendly Version
02/16/18Pacira Pharmaceuticals to Present at the 2018 RBC Capital Markets Healthcare Conference
PARSIPPANY, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2018 RBC Capital Markets Healthcare Conference at 9:30 AM ET on Wednesday, February 21, 2018 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website f... 
Printer Friendly Version
02/15/18Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
Company working with FDA toward April 6, 2018 PDUFA date PARSIPPANY, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), announced today that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee did not reach a unanimous decision on the efficacy and safety of the use of EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block to produce regional analgesia. The committee’s feedback will be consider... 
Printer Friendly Version
>> Access Older Press Releases